Skip to main content
Erschienen in: World Journal of Surgery 11/2005

01.11.2005

18F-Fluorodeoxyglucose Positron Emission Tomography: Useful Technique for Predicting Malignant Potential of Gastrointestinal Stromal Tumors

verfasst von: Yoichi Kamiyama, MD, Ryuusuke Aihara, MD, PhD, Toshihiro Nakabayashi, MD, PhD, Erito Mochiki, MD, PhD, Takayuki Asao, MD, PhD, Hiroyuki Kuwano, MD, PhD, Nobuo Oriuchi, MD, PhD, Keigo Endo, MD, PhD

Erschienen in: World Journal of Surgery | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

The malignant potential of gastrointestinal stromal tumors (GISTs) is difficult to diagnose before surgery because the diagnoses are based on tumor diameter and mitotic index. The progression of small GISTs is always observed because they do not seem to have malignant potential. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is a useful technique for assessing tumor activity. The objective of this study was to determine if FDG-PET is useful for predicting the malignant potential of gastric GISTs. Ten patients diagnosed with gastric GISTs participated. FDG-PET was performed on all of them before tumor resection. A whole-body image was initiated 40 minutes after the injection of 275 to 370 MBq FDG. FDG uptake was assessed by a standardized uptake value. All tumors had FDG uptake. There was a significant correlation between the FDG uptake and both the Ki67 index and the mitotic index but not the tumor diameter. The FDG uptake and malignant potential of gastric GISTs had a significant correlation. FDG-PET may be of considerable value for predicting the malignant potential of gastric GISTs before surgery. A gastric GIST with a high FDG uptake should be regarded as having malignant potential.
Literatur
1.
Zurück zum Zitat Miettinen M. Gastrointestinal stromal tumors: an immunohistochemical study of cellular differentiation. Am J Clin Pathol 1988;89:601–610PubMed Miettinen M. Gastrointestinal stromal tumors: an immunohistochemical study of cellular differentiation. Am J Clin Pathol 1988;89:601–610PubMed
2.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutation of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580CrossRefPubMed Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutation of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580CrossRefPubMed
3.
Zurück zum Zitat Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GI-PACT): gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998;152:1259–1269PubMed Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GI-PACT): gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998;152:1259–1269PubMed
4.
Zurück zum Zitat DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58CrossRefPubMed DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58CrossRefPubMed
5.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12CrossRefPubMed Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12CrossRefPubMed
6.
Zurück zum Zitat DeMatteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;5:466–477 DeMatteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;5:466–477
7.
Zurück zum Zitat Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80CrossRefPubMed Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80CrossRefPubMed
8.
Zurück zum Zitat Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;35:478–483 Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;35:478–483
9.
Zurück zum Zitat Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573–1581CrossRefPubMed Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573–1581CrossRefPubMed
10.
Zurück zum Zitat Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26CrossRefPubMed Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26CrossRefPubMed
11.
Zurück zum Zitat Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521–527PubMed Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521–527PubMed
12.
Zurück zum Zitat Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000;30:150–185PubMed Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000;30:150–185PubMed
13.
Zurück zum Zitat Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921–928PubMed Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921–928PubMed
14.
Zurück zum Zitat Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-d-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247–253CrossRefPubMed Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-d-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247–253CrossRefPubMed
15.
Zurück zum Zitat Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl. 5):S60–S65PubMed Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl. 5):S60–S65PubMed
16.
Zurück zum Zitat Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999;20:849–857PubMed Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999;20:849–857PubMed
17.
Zurück zum Zitat Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–850PubMed Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–850PubMed
18.
Zurück zum Zitat Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003;17:733–738PubMedCrossRef Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003;17:733–738PubMedCrossRef
19.
Zurück zum Zitat Jerusalem G, Hustinx R, Beguin Y, et al. PET scan imaging in oncology. Eur J Cancer 2003;39:1525–1534CrossRefPubMed Jerusalem G, Hustinx R, Beguin Y, et al. PET scan imaging in oncology. Eur J Cancer 2003;39:1525–1534CrossRefPubMed
20.
Zurück zum Zitat Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–1220PubMed Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–1220PubMed
21.
Zurück zum Zitat Wang X, Mori I, Tang W, et al. Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Jpn J Clin Oncol 2002;32:347–351CrossRefPubMed Wang X, Mori I, Tang W, et al. Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Jpn J Clin Oncol 2002;32:347–351CrossRefPubMed
22.
Zurück zum Zitat Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999;34:416–424CrossRefPubMed Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999;34:416–424CrossRefPubMed
23.
Zurück zum Zitat Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003;43:118–126CrossRefPubMed Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003;43:118–126CrossRefPubMed
24.
Zurück zum Zitat Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669–676PubMed Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669–676PubMed
Metadaten
Titel
18F-Fluorodeoxyglucose Positron Emission Tomography: Useful Technique for Predicting Malignant Potential of Gastrointestinal Stromal Tumors
verfasst von
Yoichi Kamiyama, MD
Ryuusuke Aihara, MD, PhD
Toshihiro Nakabayashi, MD, PhD
Erito Mochiki, MD, PhD
Takayuki Asao, MD, PhD
Hiroyuki Kuwano, MD, PhD
Nobuo Oriuchi, MD, PhD
Keigo Endo, MD, PhD
Publikationsdatum
01.11.2005
Erschienen in
World Journal of Surgery / Ausgabe 11/2005
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0045-6

Weitere Artikel der Ausgabe 11/2005

World Journal of Surgery 11/2005 Zur Ausgabe

Invited Commentary

Invited Commentary

OriginalPaper

Editorial

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.